Stocks · News reference
Immutep Limited reported health-related quality of life (HRQoL) data from its investigator-initiated EFTISARC-NEO Phase II trial, which is being presented at the ESMO Congress 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immutep Limited announced the receipt of a €1.36 million (approximately A$2.16 million) cash payment from the French Government under the Crédit d'Impôt Recherche (CIR) program for 2025 R&D activities.
• Late-breaking poster will present data from the first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce